SCHEMBL2328992

SCHEMBL2328992

CCOP(=O)(O)CC(=O)c1cc(OC)c(F)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
PYGL P06737 3/20 0.37
KMT2A Q03164 3/20 0.35
MEN1 O00255 1/20 0.35
NR1I2 O75469 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HMGCR P04035 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
MITF O75030 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
POLB P06746 2/20 0.33
APEX1 P27695 1/20 0.33
LMNA P02545 1/20 0.33
RECQL P46063 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322050 0.88 POLB (0.43) NPC1MAPTRAB9AKMT2AMEN1
SCHEMBL2328989 0.82 RAB9A (0.43) NPC1MAPTRAB9APYGLKMT2A
SCHEMBL1549681 0.78 KMT2A (0.42) NPC1RAB9APYGLKMT2AMEN1
SCHEMBL2331699 0.77 RAB9A (0.40) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL2322162 0.75 KMT2A (0.53) NPC1MAPTKMT2AMEN1NR1I2
SCHEMBL2324765 0.75 TAS1R3 (0.47) MAPTKMT2AMEN1NR1I2TDP1
SCHEMBL2325440 0.73 NPC1 (0.50) NPC1MAPTRAB9AKMT2AALDH1A1
SCHEMBL2324615 0.72 CES2 (0.45) MAPTRAB9AKMT2AMEN1ALDH1A1
SCHEMBL2324778 0.72 CES2 (0.45) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL25256373 0.72 RAB9A (0.48) NPC1MAPTRAB9APYGLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 NPC1 655/4885MAPT 2099/4885RAB9A 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.